Yuya Sudo
YOU?
Author Swipe
View article: Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation
Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation Open
Among patients with NVAF who were aged ≥80 years, the incidence of cardiovascular events was lower in the Xa-I users than in the non-Xa-I users.
View article: Impact of an Intensive Lipid-Lowering Therapy Protocol on Achieving Target Low-Density Lipoprotein Cholesterol Levels in Patients With Acute Coronary Syndrome
Impact of an Intensive Lipid-Lowering Therapy Protocol on Achieving Target Low-Density Lipoprotein Cholesterol Levels in Patients With Acute Coronary Syndrome Open
Implementing the ILLT protocol using statins and ezetimibe helped achieve the target LDL-C level early in patients with ACS and may consequently improve prognosis. However, patients with LDL-C levels ≥146 mg/dL on admission may need more i…
View article: Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation
Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation Open
Background A lower serum eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (EPA/AA) level correlates with cardiovascular events. Nevertheless, elevated serum EPA levels increase the risk of new‐onset atrial fibrillation (AF) in ol…
View article: Pre-procedural Stratification by the Endothelial Function in Patients with Heart Failure Undergoing Atrial Fibrillation Ablation
Pre-procedural Stratification by the Endothelial Function in Patients with Heart Failure Undergoing Atrial Fibrillation Ablation Open
The endothelial function assessment enabled the risk stratification of clinically problematic outcomes after AF ablation in patients with HF.
View article: Serial changes in the trends of direct oral anticoagulant use and incidence of thromboembolisms and major bleeding events in very old patients with non-valvular atrial fibrillation
Serial changes in the trends of direct oral anticoagulant use and incidence of thromboembolisms and major bleeding events in very old patients with non-valvular atrial fibrillation Open
Aims Direct oral anticoagulants (DOACs) have become the first-line antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF). During this period, the incidence of thromboembolisms and major bleeding events has decreas…
View article: Cardiovascular events and death after catheter ablation in very old patients with nonvalvular atrial fibrillation
Cardiovascular events and death after catheter ablation in very old patients with nonvalvular atrial fibrillation Open
In very old NVAF patients using DOACs, those who underwent AF ablation had a lower incidence of both cardiovascular events and death than those who received medical therapy only.
View article: Relationship Between Endothelial Dysfunction and the Outcomes After Atrial Fibrillation Ablation
Relationship Between Endothelial Dysfunction and the Outcomes After Atrial Fibrillation Ablation Open
Background Endothelial dysfunction (ED) is associated with cardiovascular events in patients with atrial fibrillation (AF). However, the utility of ED as a prognostic marker after AF ablation supplementary to the CHA 2 DS 2 ‐VASc score is …
View article: Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure
Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure Open
The number of elderly patients with acute decompensated heart failure (ADHF) is increasing, and it is often difficult to treat. This study aimed to evaluate the efficacy and safety of using tolvaptan early after hospitalization in elderly …
View article: Impact of direct oral anticoagulant use on mortality in very old patients with non-valvular atrial fibrillation
Impact of direct oral anticoagulant use on mortality in very old patients with non-valvular atrial fibrillation Open
Background the efficacy and safety of direct oral anticoagulants (DOACs) compared with that of warfarin in very old patients with non-valvular atrial fibrillation (NVAF) have been reported in terms of thromboembolisms and bleeding. However…
View article: Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination Open
Myocarditis is an adverse event associated with coronavirus disease 2019 (COVID‐19) mRNA vaccination. A 50‐year‐old man presented with dyspnea and resting chest pain after receiving the second dose of the COVID‐19 mRNA vaccine and develope…